Te­va agrees to pay $225M in fines to set­tle DOJ charges of price-fix­ing gener­ic drugs

Te­va Phar­ma­ceu­ti­cals $TE­VA is dol­ing out $225 mil­lion in fines over the next five years af­ter it came to an agree­ment with the US De­part­ment of Jus­tice (DOJ) to set­tle three charges of price-fix­ing, the Is­raeli drug­mak­er an­nounced Mon­day.

Te­va will pay $22.5 mil­lion each year from 2024 through 2027 and $135 mil­lion in 2028, as well as do­nate $50 mil­lion worth of two gener­ic prod­ucts to hu­man­i­tar­i­an or­ga­ni­za­tions. Un­der the agree­ment, Te­va has al­so agreed to di­vest a gener­ic prod­uct to a third-par­ty buy­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER